Table 2.
Strain | Description | Antibody added | Avg (SD) % of cells with spheres attacheda |
---|---|---|---|
CJ1827 | Wild type | No antibody | 0.6 (0.5) |
CJ1827 | Wild type | Anti-myc | 0.6 (1.1) |
CJ2083 | remA::myc-tag-1 | No antibody | 0.0 (0.0) |
CJ2083 | remA::myc-tag-1 | Anti-myc | 52.3 (3.2) |
CJ2077 | remA::myc-tag-3 | Anti-myc | 0.0 (0.0) |
CJ2112 | remA::myc-tag-4 | Anti-myc | 33.3 (3.1) |
CJ2073 | remA::myc-tag-5 | Anti-myc | 0.3 (0.5) |
CJ2089 | Δ(gldN-gldO) remA::myc-tag-1 | Anti-myc | 0.0 (0.0) |
CJ2089 with pTB79 carrying gldN | Δ(gldN-gldO) remA::myc-tag-1/pTB79 (gldN) | Anti-myc | 52.0 (3.0) |
CJ2097 | remA::myc-tag-1 sprF | Anti-myc | 52.6 (4.0) |
Purified anti-myc-tag antiserum and 0.5-μm-diameter protein G-coated polystyrene spheres were added to cells as described in Materials and Methods. Samples were introduced into a tunnel slide, incubated for 1 min at 25°C, and examined using a phase-contrast microscope. Images were recorded for 30 s, and 100 randomly selected cells were examined for the presence of spheres that remained attached to the cells during this time. The numbers in parentheses are standard deviations calculated from three measurements.